Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 120

1.

Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling.

Klein M, Schermuly RT, Ellinghaus P, Milting H, Riedl B, Nikolova S, Pullamsetti SS, Weissmann N, Dony E, Savai R, Ghofrani HA, Grimminger F, Busch AE, Schäfer S.

Circulation. 2008 Nov 11;118(20):2081-90. doi: 10.1161/CIRCULATIONAHA.108.779751. Epub 2008 Oct 27.

PMID:
18955668
2.

Chromanol 293B binding in KCNQ1 (Kv7.1) channels involves electrostatic interactions with a potassium ion in the selectivity filter.

Lerche C, Bruhova I, Lerche H, Steinmeyer K, Wei AD, Strutz-Seebohm N, Lang F, Busch AE, Zhorov BS, Seebohm G.

Mol Pharmacol. 2007 Jun;71(6):1503-11. Epub 2007 Mar 8. Erratum in: Mol Pharmacol. 2007 Sep;72(3):796.

PMID:
17347319
3.

Biochemistry and pharmacology of novel anthranilic acid derivatives activating heme-oxidized soluble guanylyl cyclase.

Schindler U, Strobel H, Schönafinger K, Linz W, Löhn M, Martorana PA, Rütten H, Schindler PW, Busch AE, Sohn M, Töpfer A, Pistorius A, Jannek C, Mülsch A.

Mol Pharmacol. 2006 Apr;69(4):1260-8. Epub 2005 Dec 6.

PMID:
16332991
4.

Insulin-sensitizing and cardiovascular effects of the sodium-hydrogen exchange inhibitor, cariporide, in the JCR: LA-cp rat and db/db mouse.

Russell JC, Proctor SD, Kelly SE, Löhn M, Busch AE, Schäfer S.

J Cardiovasc Pharmacol. 2005 Dec;46(6):746-53.

PMID:
16306797
5.

Effects of combined inhibition of the Na+-H+ exchanger and angiotensin-converting enzyme in rats with congestive heart failure after myocardial infarction.

Ruetten H, Gehring D, Hiss K, Schindler U, Gerl M, Busch AE, Schaefer S.

Br J Pharmacol. 2005 Nov;146(5):723-31.

6.

Impaired left ventricular relaxation in type 2 diabetic rats is related to myocardial accumulation of N(epsilon)-(carboxymethyl) lysine.

Schäfer S, Huber J, Wihler C, Rütten H, Busch AE, Linz W.

Eur J Heart Fail. 2006 Jan;8(1):2-6. Epub 2005 Aug 8. Erratum in: Eur J Heart Fail. 2006 Oct;8(6):662.

7.

Dietary bread crust advanced glycation end products bind to the receptor for AGEs in HEK-293 kidney cells but are rapidly excreted after oral administration to healthy and subtotally nephrectomized rats.

Somoza V, Lindenmeier M, Hofmann T, Frank O, Erbersdobler HF, Baynes JW, Thorpe SR, Heidland A, Zill H, Bek S, Huber J, Weigle T, Scheidler S, Busch AE, Sebeková K.

Ann N Y Acad Sci. 2005 Jun;1043:492-500.

PMID:
16037271
8.

Renal accumulation and clearance of advanced glycation end-products in type 2 diabetic nephropathy: effect of angiotensin-converting enzyme and vasopeptidase inhibition.

Wihler C, Schäfer S, Schmid K, Deemer EK, Münch G, Bleich M, Busch AE, Dingermann T, Somoza V, Baynes JW, Huber J.

Diabetologia. 2005 Aug;48(8):1645-53. Epub 2005 Jul 12.

PMID:
16010524
9.

Long term Rho-kinase inhibition ameliorates endothelial dysfunction in LDL-Receptor deficient mice.

Steioff K, Rütten H, Busch AE, Plettenburg O, Ivashchenko Y, Löhn M.

Eur J Pharmacol. 2005 Apr 11;512(2-3):247-9.

PMID:
15840411
10.

Down-regulation of calpain 9 is linked to hypertensive heart and kidney disease.

Markmann A, Schäfer S, Linz W, Löhn M, Busch AE, Wohlfart P.

Cell Physiol Biochem. 2005;15(1-4):109-16.

11.

Inhibition of Rho-kinase stimulates nitric oxide-independent vasorelaxation.

Löhn M, Steioff K, Bleich M, Busch AE, Ivashchenko Y.

Eur J Pharmacol. 2005 Jan 10;507(1-3):179-86. Epub 2004 Dec 31.

PMID:
15659308
12.

Effects of the atrial antiarrhythmic drug AVE0118 on cardiac ion channels.

Gögelein H, Brendel J, Steinmeyer K, Strübing C, Picard N, Rampe D, Kopp K, Busch AE, Bleich M.

Naunyn Schmiedebergs Arch Pharmacol. 2004 Sep;370(3):183-92. Epub 2004 Aug 31.

PMID:
15340774
13.

Nephroprotection in Zucker diabetic fatty rats by vasopeptidase inhibition is partly bradykinin B2 receptor dependent.

Schäfer S, Schmidts HL, Bleich M, Busch AE, Linz W.

Br J Pharmacol. 2004 Sep;143(1):27-32. Epub 2004 Aug 2.

14.
15.

Inhibition of Na+-H+ exchange by cariporide reduces inflammation and heart failure in rabbits with myocardial infarction.

Rungwerth K, Schindler U, Gerl M, Schäfer S, Licher T, Busch AE, Ruetten H.

Br J Pharmacol. 2004 Aug;142(7):1147-54. Epub 2004 Jul 5.

16.

Atrial-selective antiarrhythmic actions of novel Ikur vs. Ikr, Iks, and IKAch class Ic drugs and beta blockers in pigs.

Knobloch K, Brendel J, Rosenstein B, Bleich M, Busch AE, Wirth KJ.

Med Sci Monit. 2004 Jul;10(7):BR221-8. Epub 2004 Jun 29.

PMID:
15232496
17.

Inhibitors of ATP-sensitive potassium channels in guinea pig isolated ischemic hearts.

Weyermann A, Vollert H, Busch AE, Bleich M, Gögelein H.

Naunyn Schmiedebergs Arch Pharmacol. 2004 Apr;369(4):374-81. Epub 2004 Mar 16.

PMID:
15024553
18.

Chronic vasopeptidase inhibition normalizes diabetic endothelial dysfunction.

Schäfer S, Steioff K, Linz W, Bleich M, Busch AE, Löhn M.

Eur J Pharmacol. 2004 Jan 26;484(2-3):361-2.

PMID:
14744624
19.

The vasopeptidase inhibitor AVE7688 ameliorates Type 2 diabetic nephropathy.

Schäfer S, Linz W, Vollert H, Biemer-Daub G, Rütten H, Bleich M, Busch AE.

Diabetologia. 2004 Jan;47(1):98-103. Epub 2003 Nov 14.

PMID:
14618238
20.

Vasopeptidase inhibition prevents nephropathy in Zucker diabetic fatty rats.

Schäfer S, Linz W, Bube A, Gerl M, Huber J, Kürzel GU, Bleich M, Schmidts HL, Busch AE, Rütten H.

Cardiovasc Res. 2003 Nov 1;60(2):447-54.

PMID:
14613875
21.

Atrial effects of the novel K(+)-channel-blocker AVE0118 in anesthetized pigs.

Wirth KJ, Paehler T, Rosenstein B, Knobloch K, Maier T, Frenzel J, Brendel J, Busch AE, Bleich M.

Cardiovasc Res. 2003 Nov 1;60(2):298-306.

PMID:
14613859
22.

Effect of chronic treatment with the vasopeptidase inhibitor AVE 7688 and ramipril on endothelial function in atherogenic diet rabbits.

Weckler N, Leitzbach D, Kalinowski L, Malinski T, Busch AE, Linz W.

J Renin Angiotensin Aldosterone Syst. 2003 Sep;4(3):191-6. Erratum in: J Renin Angiotensin Aldosterone Syst. 2004 Jun;5(2):58. Kalinowki, Ludmila [corrected to Kalinowski, Leszek].

PMID:
14608526
23.

Molecular basis for Kv1.5 channel block: conservation of drug binding sites among voltage-gated K+ channels.

Decher N, Pirard B, Bundis F, Peukert S, Baringhaus KH, Busch AE, Steinmeyer K, Sanguinetti MC.

J Biol Chem. 2004 Jan 2;279(1):394-400. Epub 2003 Oct 25.

24.

NHE-1 inhibition: from protection during acute ischaemia/reperfusion to prevention/reversal of myocardial remodelling.

Linz WJ, Busch AE.

Naunyn Schmiedebergs Arch Pharmacol. 2003 Oct;368(4):239-46. Epub 2003 Sep 19. Review.

PMID:
14504689
25.

Fluid shear stress differentially regulates gpr3, gpr6, and gpr12 expression in human umbilical vein endothelial cells.

Uhlenbrock K, Huber J, Ardati A, Busch AE, Kostenis E.

Cell Physiol Biochem. 2003;13(2):75-84.

26.

C-terminal interaction of KCNQ2 and KCNQ3 K+ channels.

Maljevic S, Lerche C, Seebohm G, Alekov AK, Busch AE, Lerche H.

J Physiol. 2003 Apr 15;548(Pt 2):353-60. Epub 2003 Mar 14.

27.

Molecular mechanisms of early electrical remodeling: transcriptional downregulation of ion channel subunits reduces I(Ca,L) and I(to) in rapid atrial pacing in rabbits.

Bosch RF, Scherer CR, Rüb N, Wöhrl S, Steinmeyer K, Haase H, Busch AE, Seipel L, Kühlkamp V.

J Am Coll Cardiol. 2003 Mar 5;41(5):858-69.

28.

[Management of high blood pressure and cardiac insufficiency. New drugs and therapeutic concepts].

Schäfer S, Busch AE.

Pharm Unserer Zeit. 2003;32(1):54-9. Review. German. No abstract available.

PMID:
12577761
29.

[Intervention in the renin-angiotensin and kallikrein-kinin systems. Pharmacologic basis of the action of ACE inhibitors].

Linz W, Busch AE.

Pharm Unserer Zeit. 2003;32(1):18-22. Review. German. No abstract available.

PMID:
12577756
30.

RAGE-mediated MAPK activation by food-derived AGE and non-AGE products.

Zill H, Bek S, Hofmann T, Huber J, Frank O, Lindenmeier M, Weigle B, Erbersdobler HF, Scheidler S, Busch AE, Faist V.

Biochem Biophys Res Commun. 2003 Jan 10;300(2):311-5.

PMID:
12504085
31.

The antihistamine fexofenadine does not affect I(Kr) currents in a case report of drug-induced cardiac arrhythmia.

Scherer CR, Lerche C, Decher N, Dennis AT, Maier P, Ficker E, Busch AE, Wollnik B, Steinmeyer K.

Br J Pharmacol. 2002 Nov;137(6):892-900.

32.
33.

Comparative analysis of human and rat S1P(5) (edg8): differential expression profiles and sensitivities to antagonists.

Niedernberg A, Scherer CR, Busch AE, Kostenis E.

Biochem Pharmacol. 2002 Oct 15;64(8):1243-50.

PMID:
12234605
34.

Inhibition of cardiac potassium currents by pentobarbital.

Bachmann A, Mueller S, Kopp K, Brueggemann A, Suessbrich H, Gerlach U, Busch AE.

Naunyn Schmiedebergs Arch Pharmacol. 2002 Jan;365(1):29-37. Epub 2001 Nov 8.

PMID:
11862331
35.

Gene expression profiles of CLC chloride channels in animal models with different cardiovascular diseases.

Scherer CR, Linz W, Busch AE, Steinmeyer K.

Cell Physiol Biochem. 2001;11(6):321-30.

36.

A kinetic study on the stereospecific inhibition of KCNQ1 and I(Ks) by the chromanol 293B.

Seebohm G, Lerche C, Pusch M, Steinmeyer K, Brüggemann A, Busch AE.

Br J Pharmacol. 2001 Dec;134(8):1647-54.

37.

DCPIB is a novel selective blocker of I(Cl,swell) and prevents swelling-induced shortening of guinea-pig atrial action potential duration.

Decher N, Lang HJ, Nilius B, Brüggemann A, Busch AE, Steinmeyer K.

Br J Pharmacol. 2001 Dec;134(7):1467-79.

38.

Characterization of a novel Kv1.5 channel blocker in Xenopus oocytes, CHO cells, human and rat cardiomyocytes.

Bachmann A, Gutcher I, Kopp K, Brendel J, Bosch RF, Busch AE, Gögelein H.

Naunyn Schmiedebergs Arch Pharmacol. 2001 Nov;364(5):472-8.

PMID:
11692231
39.

Synthesis and activity of novel and selective I(Ks)-channel blockers.

Gerlach U, Brendel J, Lang HJ, Paulus EF, Weidmann K, Brüggemann A, Busch AE, Suessbrich H, Bleich M, Greger R.

J Med Chem. 2001 Nov 8;44(23):3831-7.

PMID:
11689069
40.

hKChIP2 is a functional modifier of hKv4.3 potassium channels: cloning and expression of a short hKChIP2 splice variant.

Decher N, Uyguner O, Scherer CR, Karaman B, Yüksel-Apak M, Busch AE, Steinmeyer K, Wollnik B.

Cardiovasc Res. 2001 Nov;52(2):255-64.

PMID:
11684073
41.

Dependence of I(Ks) biophysical properties on the expression system.

Seebohm G, Lerche C, Busch AE, Bachmann A.

Pflugers Arch. 2001 Sep;442(6):891-5.

PMID:
11680622
42.
44.

Identification of specific pore residues mediating KCNQ1 inactivation. A novel mechanism for long QT syndrome.

Seebohm G, Scherer CR, Busch AE, Lerche C.

J Biol Chem. 2001 Apr 27;276(17):13600-5. Epub 2001 Jan 17.

45.

Characterization of TASK-4, a novel member of the pH-sensitive, two-pore domain potassium channel family.

Decher N, Maier M, Dittrich W, Gassenhuber J, Brüggemann A, Busch AE, Steinmeyer K.

FEBS Lett. 2001 Mar 9;492(1-2):84-9.

46.

Molecular impact of MinK on the enantiospecific block of I(Ks) by chromanols.

Lerche C, Seebohm G, Wagner CI, Scherer CR, Dehmelt L, Abitbol I, Gerlach U, Brendel J, Attali B, Busch AE.

Br J Pharmacol. 2000 Dec;131(8):1503-6.

47.

Inhibition of IKs channels by HMR 1556.

Gögelein H, Brüggemann A, Gerlach U, Brendel J, Busch AE.

Naunyn Schmiedebergs Arch Pharmacol. 2000 Dec;362(6):480-8.

PMID:
11138839
48.

Molecular cloning and functional expression of KCNQ5, a potassium channel subunit that may contribute to neuronal M-current diversity.

Lerche C, Scherer CR, Seebohm G, Derst C, Wei AD, Busch AE, Steinmeyer K.

J Biol Chem. 2000 Jul 21;275(29):22395-400.

49.

The K(ATP) channel blocker HMR 1883 does not abolish the benefit of ischemic preconditioning on myocardial infarct mass in anesthetized rabbits.

Jung O, Englert HC, Jung W, Gögelein H, Schölkens BA, Busch AE, Linz W.

Naunyn Schmiedebergs Arch Pharmacol. 2000 Apr;361(4):445-51.

PMID:
10763861
50.

K(ATP) channel blocker HMR 1883 reduces monophasic action potential shortening during coronary ischemia in anesthetised pigs.

Wirth KJ, Uhde J, Rosenstein B, Englert HC, Gögelein H, Schölkens BA, Busch AE.

Naunyn Schmiedebergs Arch Pharmacol. 2000 Feb;361(2):155-60.

PMID:
10685870

Supplemental Content

Loading ...
Support Center